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Abstract: Keratins are naturally derived proteins that can be fabricated into several biomaterials morphologies including 
films, sponges and hydrogels. As a physical matrix, keratin biomaterials have several advantages of both natural and syn-
thetic materials that are useful in tissue engineering and controlled released applications. Like other naturally derived pro-
tein biomaterials, such as collagen, keratin possess amino acid sequences, similar to the ones found on extracellular matrix 
(ECM), that may interact with integrins showing their ability to support cellular attachment, proliferation and migration. 
The ability of developing biomaterials that mimic ECM has the potential to control several biological processes and this is 
the case for keratin which has been used in a variety of biomedical applications due to its biocompatibility and biodegrad-
ability. This review describes the progress to date towards the use of keratin in the field of wound healing, tissue engineer-
ing and drug delivery applications, with highlight to reports of particular relevance to the development of the underlying 
biomaterials science in this area. 
Keywords: Biomaterials, cell proliferation, drug delivery, films, keratin, oxidative extraction, reductive extraction, scaffolds, 
wound healing. 
1. INTRODUCTION 
 Biomaterial is a material that replaces either a tissue or a 
function within the body [1]. For this purpose many re-
searchers have explored the use of natural polymers due to 
their intrinsic ability to perform very specific biochemical 
and structural roles. The similarity between natural polymers 
and the macromolecules forming the extracellular matrix 
(ECM) suggests an innate ability to interact with cells from 
the host tissues presenting better biocompatibility when 
compared to synthetic materials [2, 3]. Several natural poly-
mers such as fibrin, fibronectin, collagen, elastin, gelatin, 
alginate, silk fibroin, chitosan and hyaluronic acid have been 
widely used in a broad spectrum of biomaterial development. 
In particular, proteins are considered a sophisticated group 
due to their ability to function as a synthetic ECM [4]. 
Within this group, keratin protein has emerged as potential 
biopolymers for the fabrication of new biomaterials. Ad-
vances in the extraction, purification and characterization of 
keratin proteins derived from wool and human hair, have led 
to the development of a keratin-based biomaterials platform. 
Keratin is characterized by highly repetitive amino acid se-
quences that result in the formation of relatively homogene-
ous secondary structures via self-assembly. Its ability to self-
assemble into various physical states such as films, sponges 
and nanoparticles was exploited for the development of new 
biomaterials with improved properties that allow their appli-
cation in controlled delivery systems and tissue engineering. 
This review addresses the properties of keratin and its use on 
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biomaterial production that target different biomedical appli-
cations. 
2. KERATIN PROPERTIES 
 Keratin is the major structural fibrous protein providing 
outer covering such as hair, wool, feathers, nails and horns of 
mammals, reptiles and birds [5]. Keratin proteins are self-
assembled into fibers in the follicle by a high proliferative 
process controlled by more than 30 growth factors and cyto-
kines [6-10]. After extrusion through the skin, the fiber is 
formed into a highly stable structure formed by covalent, 
ambient oxygen catalyzed disulfide crosslinking and non-
covalent interactions, which can occur between separate 
polypeptide chains (intermolecular) but also, between differ-
ent points of the same polypeptide chain (intramolecular). 
 Keratin fibers, such as wool and human hair, consist of 
two major morphological parts: the cuticle layer which is 
composed of overlapping cells that surround the cortex, the 
inner part of the fiber. The cortex comprises spindle-shaped 
cortical cells that are separated from each other by a cell-
membrane complex, which consists of non-keratinous pro-
teins and lipids [11-15]. The cuticle cells comprise 10% of 
the total weight and are laminar with a rectangular shape 
forming a sheath of overlapping scales surrounding the cor-
tex [13, 16, 17]. Keratin proteins can be roughly classified 
into two groups: the intermediate filament proteins (IFPs) 
and the matrix proteins. The most abundant are the IFPs also 
known as "-keratin that reside in the fiber cortex. They have 
"-helical secondary structure, are low in sulfur content and 
have an average molecular mass in the range of 40-60 kDa. 
The matrix proteins or #-keratin are globular, have a low 
molecular weight and are noted for the high content in either 
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sulfur content can be divided in high sulfur proteins (HSPs) 
or ultra-high sulfur proteins (UHSPs) depending on their 
cysteine content and have a molecular weight in the range of 
11-26 kDa. The high glycine-tyrosine proteins (HGTPs) 
have a molecular weight between 6 and 9 kDa [18-20]. The 
matrix proteins functions surround the IFPs and interact with 
them through intermolecular disulfide bonds [15]. The for-
mation of the crosslinked IF-matrix composite is crucial in 
conferring to the "-keratin their high mechanical strength, 
inertness and rigidity [21]. The packing of the IFPs com-
bined with the matrix proteins form the macrofibrils within 
the cortex [21, 22]. There is also another group of keratin 
proteins, the !-keratin. These form the majority of the cuticle 
and their function is to protect keratin fibers from physical 
and chemical damage. The !-keratin is difficult to extract 
and do not form especially useful reconstituted structures 
[22, 23].  
3. EXTRACTION OF KERATIN FROM KERATINA-
CEOUS SUBSTRATES 
 Keratins are removed from the cortex first by using 
chemicals to break the disulfide bonds that are prevalent in 
keratinized tissues. The alpha and gamma-keratins are con-
verted to their non-crosslinked forms by oxidation [22, 24-
26] or reduction [22, 27-29], during which cystine is con-
verted to either cysteic acid or cysteine, respectively. The 
free proteins extracted with denaturating solvents produce a 
solution that can be purified by filtration and dialysis. Oxida-
tive extraction with peracetic acid or hydrogen peroxide e.g., 
yields keratins referred to as “keratoses”. These are hygro-
scopic, non-disulfide crosslink, water-soluble and, suscepti-
ble to hydrolytic degradation at extremes pH values due to 
polarization of the backbone caused by the electron with-
drawing properties of the cysteic acid. These characteristics 
lead to biomaterials that can degrade relatively fast in vivo,
i.e. on the order of days to weeks. Reductive extraction 
[commonly uses dithiothreitol (DTT), 2-mercaptoethanol (2-
Me) and thioglycolic acid (TGA) with a protein extraction of 
approximately 80% [30]. Extraction with sodium bisulfite 
forms cysteine and Bunte salts residues, temporally modified 
S-sulfo group [5, 31, 32]. With this method the keratin ex-
tracted is about 30% of the total protein content of the origi-
nal wool [33]. Reduced keratins or “kerateines” are, less 
polar and as a consequence less soluble in water, more stable 
at extreme pH and, can be re-crosslinked through oxidative 
coupling of cysteine groups. This results in biomaterials that 
persist in vivo for weeks to months. Recently, it was reported 
the extraction of keratin using a hydrophobic ionic liquid 
with a maximum of keratin yield of 21% [34]. 
4. KERATIN-BASED BIOMATERIALS FABRICA-
TION  
 The interest of using keratin as a biomaterial in medical 
applications is based on several key properties that contrib-
ute to the overall physical, chemical and biological behavior 
of these biomaterials. Extracted keratin proteins have an in-
trinsic ability to self-assemble and polymerize into fibrous 
and porous films gels and scaffolds. The spontaneous self-
assembly of keratin has been studied extensively at both mi-
croscale [35-37] and macroscale levels [38]. Furthermore, 
the presence of cell adhesion sequences, arginine-glycine-
aspartic acid (RGD) and leucine-aspartic acid-valine (LDV) 
on the keratin protein derived from wool and hair, makes 
keratin biomaterials able to support cell attachment and 
growth [39, 40]. These are the same sequences found in sev-
eral extracellular matrix (ECM) proteins [41, 42]. The proc-
essing of keratin protein solutions into derivatives physical 
states such as gels, films and scaffolds start to appear in the 
literature in 1972 [43-45], then the first study using a keratin 
biomaterial appeared wherein a vascular graft coated with 
keratin was successfully implanted into a dog for more than 
200 days without thrombosis [46]. Since then, keratin have 
been studied for its application in biomaterials for wound 
healing [47-51] bone regeneration [52], hemostasis [53] and 
recently in peripheral nerve repair [54, 55]. 
4.1. Keratin Films and Coatings 
 Keratin films can be prepared by solvent casting. This 
technology is becoming increasingly attractive for the pro-
duction of films with extremely high quality requirements. 
The advantage of this technology includes uniform thickness 
distribution, maximum optical purity, and extremely low 
haze and is a technique easy to use. The ability of keratin 
solution to self-assemble into films was described by Yama-
uchi et al. [56] and, the physicochemical properties and bio-
degradability of the solvent-cast keratin films were evalu-
ated. Pure keratin films presented low mechanical strength 
but the addition of glycerol resulted in transparent films, 
with increased mechanical strength, flexible and biodegrad-
able both in vitro (trypsin) and in vivo (subcutaneous implan-
tation in mice) [56]. Furthermore, these films proven to pro-
mote and increased cell adhesion and growth when com-
pared to collagen and glass [57]. Like many natural-derived 
biomaterials, keratin-based ones present poor mechanical 
strength. As a consequence, several approaches for control-
ling the physical and biological properties have been studied 
such as, blend systems with natural [58-62] and synthetic 
[33, 63] polymers, use of crosslinking agents [64] and new 
preparation techniques [31, 65, 66]. Addition of chitosan to 
keratin forms strong and flexible films with improved swel-
ling properties. Furthermore, the composite film demon-
strated to be a good substrate for mammalian cell culture 
[60]. Lee et al. first reported keratin-silk fibroin (SF) blend 
films. This study aimed to understand the interactions that 
occur between the two proteins and how they affect the 
overall properties of the biomaterials. The results indicated 
that addition of keratin induces the transition from random 
coil to !-sheet of the SF chains. It was consider that keratin 
plays a similar role of a polar solvent due to the abundant 
polar groups in its amino acid composition [59]. Moreover, 
the antithrombogenicity and biocompatibility of keratin-SF 
films was improved when compared to pure keratin and SF 
films [67]. In a different study, the properties of keratin-SF 
films were further studied and, it was described that keratin 
and SF interactions are not simply additive but the two pro-
teins are able to establish intermolecular interactions like 
hydrogen bonding. Furthermore, degradation rates are con-
trolled by blend composition. The knowledge and strength of 
the interactions as well the degradation rates allows the de-
sign of matrices with controlled-release properties [62]. In 
addition to natural biopolymers, keratin interaction with syn-
thetic polymers has also been studied [33, 63]. The proper-
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ties of keratin films blended with poly(ethylene oxide) 
(PEO) were described by Tonin et al. [33], it was concluded 
that at appropriate levels, keratin is able to inhibit PEO crys-
tallization. Moreover, PEO interferes with the keratin self-
assembly, inducing a more thermally-stable "-sheet secon-
dary structure. The intermolecular interactions between kera-
tin and polyamide 6 (PA6) have also been studied and, the 
results indicated that the addition of keratin improves the 
miscibility and hydrophilicity [63]. Another common tech-
nique to improve the mechanical strength is the use of 
crosslinking agents. Keratin films prepared by casting a re-
duced keratin solution, were chemically crosslinked with 
ethylene glycol diglycidyl ether (EGDE) and glycerol digly-
cidyl ether (GDE) [64]. It was reported that keratin 
crosslinked films have similar mechanical properties and 
improved waterproof characteristics when compared to kera-
tin-chitosan films previously described [60]. Furthermore, 
chemical crosslinking does not have detrimental effects on 
cell biocompatibility [64]. Improved mechanical properties 
can also be achieved by alternative fabrication techniques. 
Compression molding of S-sulfo keratin powder for the pro-
duction of films was developed [31]. The mechanical proper-
ties of the films can be modulated by controlling the molding 
temperature and water content. The biocompatibility was 
also demonstrated by cell adhesion and proliferation onto the 
films [31]. Recently, Yang et al. described the use of keratin 
for layer-by-layer (LbL) self-assembly [66]. Herein, the film 
is formed by depositing alternating layers of oppositely 
charged materials. Keratin has an isoelectric point (pI) of 
3.8. Therefore, at neutral pH keratin is negatively charged 
and will act as a polyanion in LbL assembly. When the pH of 
the solution is set below its pI, the net charge of the keratin 
molecule is reversed to positive. Thus, keratin can be used as 
a polycation for LbL assembly. With this technique, keratin 
films with controlled thickness will be easily produced. In 
addition, it will be possible to easily incorporate bioactive 
compounds into the layers by electrostatic interactions. Al-
though the mechanical properties were not evaluated, it is 
clear that a multilayer film will possess an increased me-
chanical strength when compared to a unilayer film. Reichl 
et al. demonstrated two approaches for substrate coating: 
keratin precipitation with thricloroacetic acid (TCA) and 
casting a keratin nanosuspension. The latter presented im-
proved cell growth in comparison to uncoated polystyrene or 
TCA coating [68]. 
 Keratin presents high versatility as it has been used in the 
development of in vitro assays. The limited source of human 
nail plate for studying drug permeation, for the treatment of 
nail diseases, have led researchers to develop a nail plate 
model made of human hair keratin films. Keratin was ex-
tracted using reductive conditions and the films prepared by 
solvent evaporation. The produced films were suitable for 
permeation experiments with regard to its mechanical stabil-
ity and water resistant property [69]. In another study, regen-
erated keratin and ceramides were combined for the devel-
opment of membranes that simulate the stratum corneum 
[70]. The membranes can represent a simplified model to 
assay the in vitro skin permeability study for small drugs 
avoiding the use of animal or human skin. 
4.2. Keratin 3D-Constructs 
 The ability of extracted keratin to self-assemble into three 
dimensional porous structures has led to their development 
as scaffolds for biomedical applications. The sponge scaf-
folds were fabricated by lyophilization of an aqueous keratin 
solution after controlled freezing. This resulted in sponges 
with homogeneous porous microstructures. Lyophilization or 
freeze-drying technique is based upon the principle of subli-
mation. The protein solution, of desired concentration, is 
frozen and solvent is removed by lyophilization under the 
high vacuum. Porous structures are formed from the voids 
left by the removal of the solvent. Thus, the frozen solvent 
acts as porogen to produce porous materials. The pore size 
can be controlled by the freezing rate and pH; a fast freezing 
rate produces smaller pores. Wool keratin sponges were first 
reported by Tachibana et al. [39]. The sponges exhibited cell 
attachment and proliferation over a long-term cultivation 
period of 23-43 days [39]. The diameter and interconnectiv-
ity of the scaffolds pores is important for obtaining adequate 
cellular infiltration and nutrient delivery. Sponges with con-
trolled pore size and porosity were developed by Katoh et al.
by means of S-sulfo keratin sponges prepared by a compres-
sion-molded/particulate leaching (CM/PL) technique. The 
sponges presented adequate mechanical properties and were 
water-insoluble [32]. In another study, a reduced keratin so-
lution was mixed with dried calcium alginate beads. After 
lyophilization and leaching, a keratin sponge with high po-
rosity and interconnectivity was obtained, in addition to cel-
lular adhesion and growth [42]. Functionalization of the ac-
tive free cysteine residues in the keratin sponges can be 
achieved by chemical treatments with iodoacetic acid, 2-
bromoethylamine and iodoacetamide to produce carboxyl-, 
amino- and amide-sponges. These chemically-modified kera-
tin sponges have been shown to mimic ECM proteins and, 
the large presence of active groups allows further hybridiza-
tion with bioactive molecules. Tachibana et al. demonstrated 
the hybridization of keratin sponges with calcium phosphate. 
Two types of hybrids sponges were obtained by either 
chemically binding of calcium and phosphate or, by trapping 
commercially available hydroxyapatite particles within the 
modified keratin sponge. Both hybridized sponges supported 
osteoblasts cultivation and altered their differentiation pat-
tern [52]. Keratin carboxyl-sponges have also been function-
alized with bone morphogenetic protein-2 (BMP-2). BMP-2 
was confined within the modified keratin sponge, without 
protein loading into the surrounding media, which was ac-
companied by preosteoblasts differentiation and growth [71]. 
The in vivo biodegradation of keratin sponges, with bars 
shape, was assessed by subcutaneously implantation in adult 
rats [72]. It was showed a gradual decrease in the mass of the 
bars over the 18 weeks of study. On the contrary, the elastic 
modulus of the bars decrease abruptly indicating an internal 
change in the structure and shape of the keratin bars [72]. 
 Electrospining technology has become popular for the 
fabrication of scaffolds because it is a simple, rapid and effi-
cient method for producing nanofibrous mats which have 
unique properties such as high surface to volume ratio, high 
porosity and morphologically similarity to natural ECM 
which promote cell adhesion, proliferation and migration 
[73]. In recent years much attention has been focused on the  
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electrospining of biopolymers such as silk fibroin [74, 75], 
collagen [76], fibrinogen [77], gelatin [78] and elastin [79]. 
Nevertheless, keratin has not been widely used due to the 
poor mechanical properties of regenerated keratin that hin-
ders its processability and restricts its practical applications 
to blending with appropriate polymers. Yuan et al. [80] fab-
ricated the poly(hydroxybutylate-co-hydroxyvalerate) (PH 
BV)/keratin composite nanofibrous mats concluding that the 
presence of keratin produced beads on the mats due to the 
broad molecular weight distribution and low dissolvality of 
keratin. In another study, wool keratin was used to improve 
the cell affinity of poly(L-lactic acid) (PLLA) [81]. 
PLLA/keratin nonwoven fibrous was produced by electro-
spining of the blend solutions and osteoblasts cells were used 
to evaluate the cellular behavior of the composite membrane. 
The results indicated that the presence of keratin improved 
the interactions between osteoblast cells and the polymeric 
membranes. Aluigi et al. fabricated composite nanofibers 
consisted of keratin and poly(ethyleneoxide) (PEO) using 
water as a solvent. As a result, regularly shaped nanofibers 
could be obtained at the ratio of 50/50 and polymer concen-
tration of 7-10% [82, 83]. In an additional study, they evalu-
ated the chemical, physical and rheological characteristics of 
electrospun PEO/keratin mats concluding that the presence 
of keratin increase the viscosity of the solutions [84]. Re-
cently, the same author produced mats of wool keratin and 
polyamide 6 (PA6) blends to be evaluated as adsorbents of 
copper (II) ions, the adsorption tests revealed that keratin-
based nanofibers highly adsorb copper ions and its highly 
pH-dependent, being the optimum pH above the isoelectric 
point of keratin [85]. In a different study, keratin was modi-
fied with iodoacetic acid to enhance its solubility in organic 
solvent. Modified keratin was further blended with PEO and 
electrospun to produce mats. The results indicated that the 
nanofibers become thinner and more homogeneous due to 
the presence of keratin with an enhanced cell adhesion and 
proliferation [86].  
5. KERATIN-BASED DRUG DELIVERY SYSTEMS 
 Drug delivery which takes into consideration the carrier, 
the route of administration and the target, has evolved into a 
strategy of processes and devices designed to enhance the 
efficacy of therapeutic agents through controlled release. For 
many drug applications controlled drug delivery has even 
become a prerequisite to achieve therapeutic efficacy and/or 
avoid adverse side effects [87, 88]. Controlled drug delivery 
systems are not only to protect and stabilize the incorporated 
drug but also help to maintain significant local levels for 
sustained therapeutic response at low frequency of admini-
stration. Biomaterials for controlled drug delivery systems 
have to meet several requirements. They need to be biocom-
patible, biodegradable, non-toxic, cheap and easy to process. 
The ability to fabricate a variety of drug delivery constructs 
with different morphologies such as films, gels, foams, mi-
croparticles and scaffolds contributes to a broad application 
spectrum of the biomaterial. Mild processing technologies 
are preferred, and the amount of organic solvents must be 
minimized when sensitive agents are incorporated in order to 
reduce toxic effects of residual solvents. Moreover, the re-
lease profiles of a delivery system should be adjustable in 
order to achieve spatiotemporal control of clinically relevant 
therapeutic concentrations. A variety of polymers have been 
investigated for drug delivery purposes. Synthetic macro-
molecules including polyesters, polyorthoesters, polyanhy-
drides, polyphosphazenes, and polyphosphoesters have 
found broad application [89]. Natural polymers including 
alginates, chitosan, cellulose, collagen, gelatin, silk fibroin 
and elastin remain attractive due to their biocompatibility 
and biodegradability, their similarity to biological macro-
molecules and the potential for chemical or physical modifi-
cation [2, 90]. However, there remains a need for biomateri-
als that can be highly controlled in terms of composition and 
sequence, structure and architecture, mechanical properties 
and function. To address these requirements, the exploration 
of keratin as a biomaterial for controlled drug delivery has 
widely expanded over the last few years. This article will 
review recent developments in this area of research. 
 Natural polymers have the advantage of being rich in 
reactive chemical groups (hydroxyl, carboxyl, amide, sulf-
hydryl) which make them more hydrophilic and capable of 
interacting with bioactive molecules. The most common and 
easiest way of incorporating drugs into keratin biomaterials 
is by dissolving or mixing them directly into the keratin solu-
tion before processing. The challenge of this method is to 
ensure that there is no detrimental impact of the fabrication 
process on the integrity and bioactivity of the drug. Such 
protocols were suggested for the preparation of drug loaded 
keratin films [91, 92]. Fujii et al. developed a new procedure 
for the extraction of keratin from human hair without a sur-
factant agent, with a protein extraction yield greater than 
70%. The developed films were effective on the controlled-
release of alkaline phosphatase (ALP) that retains its bio-
logical activity after incorporation into keratin films for at 
least 14 days [91]. In another study, blend films of keratin 
and silk fibroin (SF/K films) were developed to incorporate 
small peptide sequences with the ability to control the activ-
ity of human neutrophil elastase (HNE). To evaluate the re-
lease mechanism present, BSA-FITC was used as a model. 
The results indicated that the release is fast and is dependent 
on the keratin amount. Methanol treatment, used to induce 
insolubility of SF leads to higher crystallinity, making the 
film rigid and compact. Although this treatment leads to 
physical cross-linking of the films, incorporation of keratin, 
of hydrolytic nature, increased the release rates due to kera-
tin dissolution causing more void volume for the release of 
the compound. The results indicated that the release rate can 
be modulated by film composition and that the mechanism is 
dominated by film degradation and diffusion [92]. In this 
way, keratin can be used to increase the release in highly 
hydrophobic and non-degradable systems. Recently, keratose 
was mixed with bone morphogenetic protein 2 (BMP-2) fab-
ricated into a scaffold and implanted into a critical-size rat 
femoral defect [93]. Paracetic acid oxidation of keratin used 
to produce keratose biomaterial introduces sulfonic acids 
which confers a net negative charge to the protein chains [94, 
95]. The recombinant human BMP-2 growth factor used is 
positively charged at acid and neutral pH levels [96] which 
allows its incorporation into the scaffold through electro-
static interactions. This permits localized and controlled 
growth factor delivery, with biological functionality, during 
the bulk degradation of the keratose scaffold which in turns 
promotes the regeneration of critical-size bone defect.  
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 Drugs may alternatively be incorporated post-fabrication 
[97, 98]. Keratin was obtained by oxidative extraction yield-
ing keratose powder. This was further resuspended to form 
hydrogels and the drugs ciprofloxacin [97] and halofuginone 
[98] were incorporated in this step through electrostatics 
interactions. Keratin-ciprofloxacin and keratin-halofuginone 
hydrogels support the sustained release of the drugs over 3 
weeks and 7 days respectively, with biological activity. In 
addition, it was shown that the release is mediated by the 
keratin degradation as previously reported [92, 99]. Physical 
adsorption is a simple immobilization process and is based 
on relatively weak or moderate electrostatic, van der Waals, 
hydrogen and hydrophobic interactions, the binding stability 
of the drugs can vary depending on environmental conditions 
which can result in uncontrolled release as observed in the 
above studies. To overcome this, covalent immobilization 
has been widely used since it has the advantage of providing 
stable attachment of bioactive agents to biomaterials. This is 
an efficient strategy to control the release profile of the im-
mobilized drugs since these are retained for longer time peri-
ods at the delivery site when compared to adsorption [100]. 
In a recent study, diclofenac was added to keratin solution to 
prepared drug-loaded keratin films. These were further 
crosslinked with transglutaminase (TGase). The results indi-
cated that diclofenac release is closely related to the solubil-
ity of keratin films and, TGase crosslinking delayed the re-
lease due to the improvement of the mechanical properties of 
the films [99]. The presence of free cysteine residues within 
keratin sponges allows the immobilization of bioactive 
agents. Lysozyme was immobilized in a keratin sponge via
disulfide and thioether bonds. Disulfide-linked lysozyme was 
released over a 21-days period unlike lysozyme linked via
thioether bonds that remains in the sponge up to two months. 
This study showed that the release properties from keratin 
sponges can be controlled by the selection of the crosslinker 
[101]. Belcarz et al. demonstrated that gentamicin covalently 
bound to keratin-coated-hydroxyapatite (HAP) granules 
showed more controlled release profiles that analogues gela-
tin-coated-HAP and non-coated granules [102].  
 The incorporation of drugs into nanoparticles is another 
option. Recently, Li et al. reported the development of kera-
tin-g-polyethylene glycol (PEG) nanoparticles loaded with 
doxorubicin (DOX). The results indicated that the loading 
efficiency increases with the increase of the keratin content 
on the keratin-g-PEG nanoparticles due to the formation of 
hydrogen bonds between keratin and the drug. DOX release 
was investigated at glutathione (GSH) concentrations corre-
sponding to those present in cells and blood plasma. It was 
shown that higher release rates are obtained at intracellular 
level (higher GSH concentration) with efficient internaliza-
tion showing the promising applications of keratin-g-PEG as 
drug carriers for cancer therapy [103].  
6. KERATIN IN BIOMEDICAL APPLICATIONS 
 Keratin have a strong potential for development as clini-
cally relevant biomaterials because they are abundant, bioac-
tive and a realistic source of autologous proteins. Several 
studies have been made to evaluate the use of keratin in bio-
medical applications. Recently, keratin films were used for 
ocular surface reconstruction [104] that uses human amniotic 
membrane (AM). The results suggested that keratin films 
could represent the replacement of the amniotic membrane in 
ophthalmology because keratin films are more transparent 
and stiffer than AM with similar levels of corneal epithelial 
cells attachment and proliferation. Shen et al. [105] devel-
oped keratin hydrogels for the treatment of acute myocardial 
infarction. Human hair derived keratin hydrogels were in-
jected in the hearts promoting angiogenesis without incre-
mental inflammation, attenuated adverse heart remodeling 
and preserved cardiac function. Aboushwareb et al. [53] re-
vealed the hemostatic properties of keratin. It was hypothe-
sized that keratin hydrogel has the ability to adsorb fluid and 
bind cells to act as an effective hemostatic agent. The results 
demonstrated that keratin hydrogel derived from human hair 
was efficient in stopping hemorrhage and improved survival 
in a rabbit model of liver injury, with comparable efficacy of 
commercial hemostatic agents. Serpinski et al. [55], Hill et
al. [106] and Lin et al. [107] demonstrated the effectiveness 
of keratin hydrogels in the promotion of peripheral nerves 
regeneration using animal models. The studies revealed that 
keratin biomaterial is neuroconductive and contain regula-
tory molecules capable of enhancing nerve tissue regenera-
tion by enhancing the activity of Schwann cells. 
 Keratin powder used as an absorbent wound dressing 
showed the promotion of skin healing due to the release of 
keratin derivative peptides to the wound [108]. Water-
soluble keratin peptides derived from an oxidative extraction 
from human hair were shown to be wound-healing agents 
enhancing the proliferation of human dermal fibroblasts [50]. 
More recently, keratin derivatives obtained either by oxida-
tive and reductive methods were applied to burn wounds 
using animal and human models. The burn wounds treated 
with keratin materials showed a decrease in wound size and 
accelerated wound healing. Cross-linked keratin powder, 
films and hydrogels showed significant proliferation of 
wound healing cell lines like microvascular endothelial cells, 
keratinocytes and fibroblasts. Moreover, incubation of kera-
tin materials with lymphocytes (T cells) and activated lym-
phocytes showed, respectively, no proliferation and normal 
growth, indicating that keratin materials are non-
immunogenic and that the body’s normal cell-mediated im-
mune response is not inhibited by keratin materials. These 
were also applied to wounds on animals (rats) and humans, 
and a faster healing of the wounds treated with keratin mate-
rials was observed and, in the human model, with reduced 
pain [47, 49]. Recently, it was investigated the biological 
mechanism underlying the observed clinical benefits of kera-
tin-based products as wound treatments [109]. The results 
suggested that the beneficial effects of keratin are related to 
its positive effects on re-epithelialization via stimulation of 
keratinocyte migration and production of collagen type IV 
and VII. Nunez et al. [110] suggested that keratose can act as 
a colloid in fluid resuscitation applications providing viscos-
ity and oncotic properties that may be beneficial during acute 
ischemic events. After infusion in cremaster muscle of rats, a 
significant vasodilation was observed. Xu et al. [111] ap-
plied human hair keratin scaffolds for subcutaneous implan-
tation and for treating full-thickness skin defects in rats. The 
data confirmed the biodegradation, biocompatibility and 
wound healing function of keratin biomaterials. Compared 
with the self-healing process of full-thickness wounds, kera-
tin scaffolds led to earlier vascularization, less contraction 
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and newly formed hair follicles. Keratin was also effectively 
blended with other components to form new wound dress-
ings. Keratin–collagen sponges were used in rats showing 
tissue compatibility and accelerated wound healing by stimu-
lating cell proliferation and vascularization [112]. An ana-
logue keratin–collagen sponge containing poly 2-hydroxy 
ethylmethacrylate was applied to burn wounds in rats. The 
composite showed healing promotion by allowing in vivo
construction of tissue engineered epidermis [113]. In another 
recent study, keratin–gelatin used in full-thickness wounds in 
dogs promoted the healing due to the early presence of hair 
follicles, sebaceous gland and normal thickness of the epi-
dermis [114]. 
7. CONCLUSIONS 
 The choice of biomaterials available continues to grow 
rapidly with new materials often claiming advantages over 
those already existing. Keratin is one of the most abundant 
proteins in mammals and it can be obtained from different 
sources including wool, human hair, and chicken feathers 
among others. Keratin biomaterials have several advantages 
of both natural and synthetic materials that are useful in 
biomedical applications. The presence of thiol groups on 
keratin biomaterials allows its functionalization and the pres-
ence of lysine and arginine residues enables it to be cleaved 
in vivo by trypsin. The better understanding of keratin prop-
erties, extraction and fabrication procedures influence the 
final characteristics of keratin biomaterials. Owing the excel-
lent biological compatibility and the promotion of cell at-
tachment and binding, keratin has experience increasing in-
terest in the field of wound healing, tissue engineering and 
controlled release applications. Nevertheless, this review 
highlights the limitations of keratin regarding its mechanical 
properties which in turn hampers its use in broader applica-
tions. The most common approach, as described herein, to 
overcome this issue is to blend keratin with other synthetic 
and natural polymers with improved mechanical properties. 
A synergistic effect is often observed, at the same time that 
the mechanical properties of keratin are improved; the bio-
compatibility of the synthetic materials in the blends is also 
enhanced. This review also demonstrated that there are few 
published studies exploring the ability to achieve the con-
trolled release of drugs from keratin biomaterials. The stud-
ies addressed herein indicated that the release of drugs from 
keratin systems is mediated by keratin degradation. There-
fore, the main challenge in controlling the drug release from 
keratin systems is to control the degradation of the devices. 
Overcoming this issue, it will be possible to exploit and de-
sign keratin devices with modulated release for several ap-
plications. In the last year, several studies were published 
highlighting the valuable properties of keratin, namely its 
biocompatibility and the intrinsic cellular recognition. How-
ever, many research results are far from clinical applications 
and commercialization. The better understanding of keratin 
properties and how they influence the final biomaterial prop-
erties will allow a broader commercialization of keratin ma-
terials.  
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